### SHORT COMMUNICATION

### **Diabetes Management**

# Smart insulin delivery systems: Transforming diabetes treatment with technology

Ermayn Esnafoglyu\*

**Received:** 14-Oct-2024, Manuscript No. FMDM-24-157453; **Editor assigned:** 17-Oct-2024, PreQC No. FMDM-24-157453 (PQ); **Reviewed:** 01-Nov-2024, QC No. FMDM-24-157453; **Revised:** 08-Nov-2024, Manuscript No. FMDM-24-157453 (R); **Published:** 15-Nov-2024, DOI: 10.37532/1758-1907.2024.14(6).687-688.

#### Description

Diabetes management has traditionally relied on daily injections of insulin to regulate blood sugar levels. While this method has been effective for many, it has also result in significant challenges, including the need for constant monitoring, the risk of errors in dosing, and the discomfort associated with injections. Smart insulin delivery refers to the use of advanced devices, such as insulin pumps, smart pens, and Continuous Glucose Monitoring (CGM) systems, to deliver insulin more precisely and automatically. These systems integrate technology that can track realtime blood glucose levels, predict insulin needs, and adjust dosages accordingly. The goal is to provide insulin delivery that more closely mimics the body's natural insulin response, improving glucose control while minimizing the risk of both high and low blood sugar levels (hypoglycemia) [1,2].

#### Key components of smart insulin delivery systems

**Continuous Glucose Monitors (CGMs):** A core feature of smart insulin delivery systems is the use of continuous glucose monitoring. CGMs are small, wearable devices that measure glucose levels in real-time by monitoring the interstitial fluid just beneath the skin. These devices can provide a steady stream of glucose data to patients and healthcare providers, enabling more accurate and timely adjustments to insulin doses [3].

CGMs can alert patients when their glucose levels are too high or too low, allowing them to take action before the situation worsens. Many CGMs can also sync with insulin pumps, creating

Department of Medicine, University of Szeged, Szeged, Hungary \*Author for correspondence: E-mail: Esnafoglyu34@gamil.com a closed-loop system where insulin delivery is adjusted automatically based on glucose readings [4,5].

**Insulin pumps:** Insulin pumps are small, computerized devices that deliver insulin continuously throughout the day, mimicking the function of a healthy pancreas. Unlike traditional insulin injections, which are given at fixed intervals, insulin pumps provide basal insulin 24/7 and allow for bolus doses (extra doses) to be administered when necessary, such as before meals or to correct high blood sugar levels.

Modern insulin pumps have become "smart," meaning they can connect to CGMs and adjust insulin delivery automatically based on realtime glucose data. Some advanced pumps can even offer features such as predictive algorithms to calculate future insulin needs and anticipate blood sugar trends [6].

Smart insulin pens: Smart insulin pens are an innovation for people with diabetes who are not using insulin pumps but still require multiple daily injections. These pens are equipped with Bluetooth technology and can track insulin doses, including timing and amount. They sync with smartphone apps, providing a digital record of insulin usage that can be reviewed by both the patient and their healthcare provider.

Smart pens also offer helpful features like dose reminders, dose calculation assistance, and insulin dose history, helping patients stay on track with their insulin therapy. Some smart pens can also send alerts when it's time for the next dose, improving patient compliance [7].





### SHORT COMMUNICATION

#### Ermayn Esnafoglyu

Artificial pancreas systems: An artificial pancreas is the ultimate goal of many smart insulin delivery systems, combining insulin pumps and CGMs to create a closed-loop system. In an artificial pancreas system, the CGM continuously monitors glucose levels, while the insulin pump adjusts insulin delivery in response. These systems are designed to replicate the function of a healthy pancreas by automatically adjusting insulin delivery based on real-time glucose data.

Advanced artificial pancreas systems also incorporate algorithms that predict blood sugar fluctuations and adjust insulin dosing ahead of time, preventing both hypoglycemia and hyperglycemia. Although artificial pancreas technology is still evolving, it offers great promise for the future of diabetes management, potentially providing a fully automated system that requires minimal input from the patient [8].

#### Benefits of smart insulin delivery

**Improved blood sugar control:** One of the primary benefits of smart insulin delivery systems is their ability to improve glucose control. By continuously monitoring blood sugar levels and adjusting insulin doses based on real-time data, these systems help maintain blood glucose within a target range more effectively.

Reduced risk of hypoglycemia: Hypoglycemia, or dangerously low blood sugar, is one of the most significant risks for people using insulin. It can cause symptoms like dizziness, confusion, and in severe cases, loss of consciousness. Smart insulin delivery systems that use CGM technology can help prevent hypoglycemia by alerting patients when their blood sugar is dropping, allowing them to take corrective action before it becomes a medical emergency.

Increased convenience: Smart insulin delivery

systems simplify daily diabetes management. Continuous insulin delivery *via* pumps or smart pens means fewer injections and less frequent manual adjustments. Patients no longer need to calculate insulin doses manually, as the devices can calculate and recommend dosages based on real-time data from the CGM [9].

**Personalized treatment:** Smart insulin delivery systems provide a level of customization that was not previously possible. The data collected by CGMs and insulin pumps allows for personalized treatment plans that are tailored to an individual's unique insulin needs. These systems can account for factors like meal timing, exercise, stress, and sleep patterns, which influence blood sugar levels, leading to a more precise and individualized approach to insulin therapy.

**Improved quality of life:** By reducing the burden of constant blood sugar monitoring and insulin injections, smart insulin delivery systems allow people with diabetes to lead more normal lives. These devices can help reduce diabetes-related stress, improve mental well-being, and enhance overall quality of life by making diabetes management less intrusive and more predictable [10].

#### Challenges and considerations

While smart insulin delivery systems offer numerous benefits, they also come with challenges. For one, they can be costly, and not all patients may have access to the necessary technology. Additionally, these systems rely on accurate sensor data, and any malfunction in the technology can potentially lead to incorrect insulin dosing. There are also concerns about data privacy and security, as the devices store and transmit personal health information. Smart insulin delivery systems: Transforming diabetes treatment with technology

## SHORT COMMUNICATION

#### References

- American Diabetes Association. Standards of Medical Care in Diabetes—2022 Abridged For Primary Care Providers. *Clin Diabetes*. 40(1):10-38 (2022).
- International Diabetes Federation. IDF Diabetes Atlas, 9<sup>th</sup> Edition. Brussels, Belgium, (2019).
- Polonsky WH, Fisher L. Self-Monitoring of Blood Glucose in Noninsulin-Using Type 2 Diabetic Patients: Right Answer, But Wrong Question: Self-Monitoring of Blood Glucose can be Clinically Valuable for Noninsulin Users. Diabetes Care. 36(1):179-182 (2013).
- 4. Dutta BJ, Singh S, Seksaria S, et al. Inside the Diabetic Brain: Insulin Resistance and

Molecular Mechanism Associated with Cognitive Impairment and its Possible Therapeutic Strategies. *Pharmacol Res.* 182:106358 (2022).

- Bergenstal RM, Ahmann AJ, Bailey T, et al. Recommendations for Standardizing Glucose Reporting and Analysis to Optimize Clinical Decision Making in Diabetes: The Ambulatory Glucose Profile (AGP). *Diabetes Technol Ther* 15(3): 198-211 (2013).
- Kullmann S, Kleinridders A, Small DM, et al. Central Nervous Pathways of Insulin Action in the Control of Metabolism and Food Intake. *Lancet Diabetes Endocrinol.* 8(6):524-534 (2020).
- 7. Rodbard D. Continuous Glucose Monitoring: A Review of Successes, Challenges, and

Opportunities. *Diabetes Technol Ther* 18(S2):S2-S3 (2016).

- Herder M, Arntzen K A, Johnsen SH, et al. Long- Term Use of Lipid- Lowering Drugs Slows Progression of Carotid Atherosclerosis: The Tromso Study 1994 to 2008. Arterioscler Thromb Vasc Biol. 33(4):858–862 (2013).
- 9. Toth PP. High-density Lipoproteins: A Consensus Statement from the National Lipid Association. J Clin Lipidol. 7, 484–525 (2013)
- 10. Hayashi T, Juliet PAR, Miyazaki A, et al. High Glucose Downregulates the Number of Caveolae in Monocytes Through Oxidative Stress from Nadph Oxidase: Implications for Atherosclerosis. *Biochim Biophys Acta*. 1772, 364-372. (2007)